Med-IQ Logo
Get CME/CE
Expert Insights on Insulin and GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes Mellitus
Webcast Webcast

Expert Insights on Insulin and GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes Mellitus


Time to Complete:
1 hour
Released:
8/25/17
Expires:
8/24/18
PDF:

Maximum Credits:

1.0 AMA PRA Category 1 Credit(s)
1.0 Accreditation Council for Pharmacy Education (ACPE)
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.

Webcast Webcast
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.
Time to Complete:
1 hour

Released:
8/25/17

Expires:
8/24/18

PDF:

Maximum Credits:
1.0 AMA PRA Category 1 Credit(s)
1.0 Accreditation Council for Pharmacy Education (ACPE)
Share on:
Webcast Webcast
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.

Share on:


Time to Complete:
1 hour
Released:
8/25/17
Expires:
8/24/18
PDF:


Maximum Credits:
1.0 AMA PRA Category 1 Credit(s)
1.0 Accreditation Council for Pharmacy Education (ACPE)


Overview: In this Webinar, experts in endocrinology and primary care present clinical evidence and answer participant questions regarding insulin intensification with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the treatment of type 2 diabetes mellitus, pharmacologic differences among available GLP-1 RAs, and strategies to address barriers that may delay the initiation of insulin therapy.

Faculty

Vivian Fonseca, MD, FRCP

Professor of Medicine

Chief, Section of Endocrinology

Tullis-Tulane Alumni Chair in Diabetes

Tulane University

New Orleans, LA

Davida Kruger, MSN, APN-BC, BC-ADM

Certified Nurse Practitioner

Division of Endocrinology, Diabetes, Bone and Mineral Disease

Henry Ford Health System

Detroit, MI


Disclosure Policy

Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.


Disclosure Statement

The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.  

Vivian Fonseca, MD, FRCP
Consulting fees/advisory boards: AstraZeneca, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Novo Nordisk, Sanofi-aventis U.S. Inc., Takeda Pharmaceuticals North America, Inc.
 
Davida Kruger, MSN, APN-BC, BC-ADM
Consulting fees/advisory boards: Abbott Laboratories, Dexcom, Inc., Eli Lilly and Company, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Novo Nordisk, Sanofi-aventis U.S. Inc.
Ownership interest (stocks/stock options – excluding mutual funds): Dexcom, Inc.
Other (speakers bureau): Abbott Laboratories, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Dexcom, Inc., Janssen Pharmaceuticals, Lilly USA, LLC, Novo Nordisk, Valeritas, Inc

The peer reviewers and activity planners have no financial relationships to disclose.


This activity has been approved for AMA PRA Category 1 Credit™.


This activity is supported by an educational grant from Sanofi US.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.
Play Video
The trifecta of healthcare improvement: value-based care, quality improvement, and technology.

See how Med-IQ is helping to enhance patient outcomes in these short videos.

Scott Weber, CEO Med-IQ

From Volume to Value-Based Care: The Role of the CME Enterprise

Scott Weber, CEO,
Med-IQ

Allison Gardner, PhD, VP Educational Strategy and Content, Med-IQ

The Value of Quality Improvement and Education to Advance Healthcare

Allison Gardner, PhD,
VP Educational Strategy and Content,
Med-IQ

Dr. Glenn Treisman,
Department of Psychiatry, Johns Hopkins Medical Institute

The Pros and Cons of Technology on the Practice of Medicine

Dr. Glenn Treisman,
Department of Psychiatry,
Johns Hopkins Medical Institute


Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or e-mail info@med-iq.com. For technical assistance, please refer to our support manual.